Filter posts

The Value of Innovation to Save and Transform Lives

Patients have greater hope for cures to today’s most complex and challenging diseases thanks to …

When The Deck is Stacked Against Innovators, Everyone Loses

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the …

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Biosimilars raise novel and complex questions of science and law that require updated legal and …

Attacks on Venture Philanthropy Miss Mark Badly

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy …

Wall Street Journal Highlights Promising Gene Therapy Advances

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American …

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling …

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of …

Jim Greenwood in WSJ: Curing Hepatitis C Is Cheaper Than Open-Ended Care

On Friday, a letter from BIO President and CEO Jim Greenwood was published in the …

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, …

Greenwood Highlights Need for Bold Action to Address Alzheimer's

Last week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), participated and …